Imagine a natural “brake” inside the body's cells that can stop the progression of cancer, only to have that brake destroyed by the cancer cells themselves. This is what happens to the p27Kip1 protein, a cell-cycle inhibitor known as a gatekeeper of cellular growth. For years, scientists have wondered: what if this brake could be engineered so that it could no longer be destroyed?
Prof. drg. Supriatno, M.Kes., MDSc., PhD., together with a research team from the Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, Japan, explored the answer through a carefully designed and controlled experiment. Their findings were published in the journal Oral Oncology in 2004, and the main finding was striking: the mutant version of the p27Kip1 gene was considerably more effective at destroying oral cancer cells than its wild-type counterpart.
When the Cellular “Brake” Is Destroyed by Cancer
To understand the importance of this research, it is first necessary to understand how cancer cells work. Every normal cell has regulatory mechanisms that control when it can divide and when it must stop. The p27Kip1 protein is one of the key regulators in this mechanism, functioning as an inhibitor of cyclin-dependent kinases (CDKs) that are active during the G1 phase of the cell cycle.
The problem is that oral cancer cells, including oral squamous cell carcinoma (SCC), have a sophisticated way of eliminating this protein. Through phosphorylation at the threonine-187 residue (Thr-187), p27Kip1 is “tagged” by the ubiquitin system within the cell and subsequently degraded. An earlier study by Prof. Supriatno's team found reduced p27Kip1 expression in 37% of the oral SCC cases they examined. Reduced levels of this protein were directly associated with poor patient prognosis.
The solution they proposed was elegant at the molecular level: simply alter the site targeted for degradation. The researchers engineered the p27Kip1 gene by replacing Thr-187/Pro-188 with Met-187/Ile-188. This small change in the amino acid sequence made the resulting protein no longer recognizable to, or degraded by, the ubiquitin system, allowing it to remain stable and active within the cell.
Laboratory Testing: Cancer Cells Halted and Shrinking
To test its effectiveness, the researchers used B88 oral cancer cells isolated from the cervical lymph node metastasis of a patient with tongue SCC. The mutant gene (p27Kip1 mt) and wild-type gene (p27Kip1 wt) were each transferred into B88 cells using the pcDNA3.1 expression vector.
The results were clear. In a six-day in vitro cell-growth assay, cells containing the mutant gene (B88-p27Kip1 mt) showed significantly greater growth inhibition than cells containing the wild-type gene or control cells, with p < 0.01. Cell-cycle analysis using flow cytometry showed that the mutant cells experienced stronger G1-phase arrest, reaching 84.4%, considerably higher than the 79.8% observed in wild-type cells and the 64.9–70.3% observed in control cells.
“Mutant type p27Kip1 gene could show more potent antitumor effects than wild type p27Kip1 gene in B88 cells… suggesting that mutant type p27Kip1 gene has the potential to become a novel and powerful gene therapy tool for patients with oral cancers.” — Supriatno et al., Oral Oncology, 2004
The findings did not stop there. Migration assays using a Boyden chamber showed that both the mutant and wild-type genes significantly suppressed the ability of cancer cells to migrate and invade surrounding tissues. Similar results were observed in the outgrowth assay, in which cells containing p27Kip1 formed almost no new colonies beyond the coverslip, unlike control cells, which grew and spread extensively.
From the Petri Dish to Rat Models: Strengthening the Evidence
Laboratory findings often appear promising but fail when tested in living organisms. This is what makes the in vivo stage of this study particularly important.
The researchers injected tumor cells into the subcutaneous tissue and tongues of nude mice. The results were consistent with the laboratory findings. Mice receiving B88-p27Kip1 mt cells developed tumors that were significantly smaller than those in the control group. More importantly, among the mice that received injections into the tongue, four out of five control mice developed metastases to the cervical lymph nodes. In contrast, none of the mice receiving cells expressing p27Kip1—either the wild-type or mutant form—developed metastases.
During the 21-day observation period, none of the mouse groups showed significant weight loss, indicating that the treatment did not cause substantial systemic toxicity.
The research team also made an important and honest observation: although the mutant gene was superior in inhibiting tumor growth, its difference from the wild-type gene in preventing cervical lymph node metastasis was not statistically significant. Both were similarly effective in this respect. This detail demonstrates the scientific rigor underlying the research.
Between Hope and the Long Road to Gene Therapy
This research is more than an academic exercise. Oral cancer, particularly oral SCC, remains a major challenge in head and neck oncology. Poor prognosis is often associated with the cancer's ability to invade surrounding tissues and metastasize to regional lymph nodes before it is detected.
The findings of Prof. Supriatno and his team raise the possibility that the mutant p27Kip1 gene could serve as a more reliable gene therapy agent because of its greater stability resulting from resistance to ubiquitin-mediated degradation. This addresses one of the major limitations of gene therapy approaches using wild-type p27Kip1: the protein produced remains vulnerable to destruction by the cellular mechanisms exploited by cancer cells.
Of course, the journey from laboratory findings to clinical application is still a long one. Testing in animal models is one step; clinical trials in humans are another, far more complex step. Yet every long journey begins with a solid point of departure, and this research represents one such starting point.
Source DOI: https://doi.org/10.1016/j.oraloncology.2004.01.002
Authors: Anny Anggraini; drg. Achmad Zam Zam Aghasy, M.Kes.
Photo: Freepik